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Abstract
Sepsis is a condition characterized by high morbidity and mortality which is commonly encountered in an
emergency and critical care setting. Despite a substantial body of research, the ideal biomarker for the
diagnosis and prognostic stratification of septic patients remains unknown. This review aimed to summarize
the publications referring to the validity of the biomarker presepsin when used for the detection, monitoring
and prognosis in patients suffering with sepsis.
This work is a narrative review based on a PubMed/Medline search conducted in order to identify all relevant
publications referring to the use of presepsin in sepsis. Search was not limited by year of publication so all
articles archived in the database would be retrieved. No article from before 2010 was identified.
A total of 57 publications of the last decade were included, all of which support the use of presepsin as a
biomarker for the assessment of septic patients. It has been used alone or in combination with commonly
used biomarkers in the evaluation of patients with sepsis in settings such as the emergency department and
the intensive care unit. It is useful in the initial workup of patients with suspected sepsis in the emergency
setting and may be a predictive factor of mortality and the most severe complication of sepsis.
Presepsin seems to be a valuable tool for the laboratory workup of sepsis, especially when used in
conjunction with other biomarkers and clinical rating scores with an established role in this population.
Further research is needed to evaluate the clinical implications of utilizing presepsin measurements in the
workup of sepsis.
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Introduction And Background
Sepsis is among the most common causes of death for hospitalized patients and despite recent progress
mortality rates remain unacceptably high, especially if septic shock is present. The financial burden of the
syndrome is significant as it commonly requires prolonged treatment in the intensive care unit [1]. The
pathogenesis of the syndrome involves a complex interplay between the pathogen (typically gram-negative
bacteria) and the host immune response. Several biomarkers have been used in clinical practice for better
monitoring, management and risk stratification of the sepsis syndrome. Presepsin is an immunologic
biomarker which has been identified during the past decade as a new, emerging, early indicator for the
detection of infections [2].
Presepsin (sCD14-ST), which is ∼13 kDa in size, is a soluble N-terminal fragment of the cluster of
differentiation marker protein CD14, which is a soluble form of the lipopolysaccharide (LPS) receptor, a
member of the family of toll-like receptors which recognize pathogen-associated molecular patterns
(PAMPs) and initiate the innate immune response [3]. LPS is a component of the gram-negative bacterial cell
wall which strongly stimulates innate immunity, thus contributing to the pathogenesis of sepsis. CD14 is a
transmembrane protein present in many cells implicated in the sepsis cascades, including macrophages,
monocytes, and granulocyte cells which is responsible for the intracellular transduction of endotoxin signals
[3]. During the process of the inflammation, soluble CD14 fragments (presepsin) are cleaved which can be
readily measured using a chemiluminescent enzyme immunoassay [2]. Because presepsin is elevated early
during sepsis and is relatively specific for bacterial infection (due to its role in the pathogenesis of sepsis as a
receptor for LPS), it may be useful in a clinical setting as a biomarker for the diagnosis and risk stratification
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of patients who are suspected to be septic. Compared to other biomarkers used for this purpose
(procalcitonin, C-reactive protein) it is hypothesized to be more specific for sepsis, as it is directly implicated
in the pathogenesis of the syndrome. Several studies have investigated the validity of presepsin when used
in clinical practice [4]. It should be noted that presepsin measurement is not ubiquitously available yet
unlike other biomarkers of sepsis. Its role as a diagnostic and prognostic biomarker for the risk stratification
of sepsis is further evaluated in clinical settings including the Emergency Department and the Intensive
Care Unit. The promising role of presepsin was reported in the review by Pizzolato in 2014, as it was noted
that presepsin had a high sensitivity and good specificity for sepsis, is readily available in the emergency
department and correlated to in-hospital mortality in patients with sepsis and septic shock. It was noted
that presepsin levels may have similar specificity and sensitivity to clinical rating systems such as the MEDS
and SOFA scores, the diagnostic and accuracy of which may be substantially improved if they are combined
with presepsin and other biomarkers [4]. The promising role of presepsin as a new biomarker for early
diagnosis of sepsis was identified in another review published the same year [5]. The authors noted that
presepsin may have better prognostic validity than procalcitonin, C-reactive protein (CRP) and the
erythrocyte sedimentation rate (ESR), while being more specific for infection compared to both lactate and
the ESR [4]. Herein we present a review of all identified bibliography which is related to the use of presepsin
in sepsis.

Review
Methods
A PubMed search was conducted on December 2020 using the terms ‘presepsin in sepsis’ as “Title/Abstract”
or as “MeSH Terms”. The structure of the search in the “Search details” window of the PubMed website was
presepsin [All Fields] AND ("sepsis"[MeSH Terms] OR "sepsis"[All Fields]). The literature search was limited
to articles referring only to adult patients and the extracted bibliography was further searched for more
related publications, by hand search of the references of retrieved articles. Studies focusing exclusively on
postoperative patients were excluded as the value of presepsin measurement in this population would best
be evaluated separately, with studies grouped based on the type of surgical procedure. Only manuscripts
written in the English language were included in this review. Though this work is a narrative review, a
PRISMA flowchart is provided (Figure 1).

FIGURE 1: Review flow chart

Results
Presepsin as a Diagnostic Marker of Infection
Several studies have evaluated the use of presepsin measurements to diagnose infection during the initial
presentation of the patient. It is hypothesized that it may be the ideal biomarker for diagnosing bacterial
infection as it is directly implicated in the innate immune response and its concentration rises within hours
of infection. This has been evaluated in a few systematic reviews and meta-analyses apart from original
studies. A meta-analysis published in 2015 evaluated presepsin for the diagnosis of sepsis based on
publications retrieved from medical databases until November 7, 2014. Eleven studies were finally included
in this meta-analysis. This systematic review showed that presepsin was an effective adjunct biomarker for
sepsis diagnosis, but insufficient to detect or rule out sepsis when used alone [6]. Another meta-analysis
published also in 2015, based on PubMed, Embase, Web of Science and Cochrane databases included eight
studies with a total of 1,815 patients. It was reported that presepsin exhibits a very good diagnostic accuracy
(Area under the curve, AUC=0.89) for the diagnosis of sepsis [7]. The same year another meta-analysis by Wu
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et al. was published based on database search up to 15 December 2014. Nine studies with 10 trials and 2159
cases were included. It was demonstrated that presepsin had some superiority in the management of
patients, and could be a helpful biomarker in sepsis early diagnosis. However, presepsin showed a moderate
diagnostic accuracy in differentiating sepsis from non-sepsis cases [8]. In 2015 another systematic review
was published, a bivariate meta-analysis based on data from PubMed and EMBASE which included 11
publications with 3,106 subjects. Presepsin found to have a valuable role in the diagnosis of sepsis, but the
results should be interpreted carefully in clinical practice and in comparison to the traditional markers [9].
One of the first clinical applications of presepsin measurement that was investigated was its use for the
initial diagnosis of infection upon patient presentation to the emergency department. For this purpose
presepsin could be used alone or in conjunction with other biomarkers commonly employed for this
purpose, such as procalcitonin (PCT) and C-reactive protein (CRP). Based upon the available evidence
presepsin is comparable in sensitivity to the aforementioned biomarkers and more specific compared to
complete blood count abnormalities such as increased white blood cell count [10], though it may not offer
any significant advantages over PCT, which is more widely available [11]. The sensitivity of presepsin
(approximately 95% with a cutoff value of 729 pg/mL for a positive test [12]) may be sufficient to rule out
infection, but it must be used in conjunction with other biomarkers and clinical scoring systems to
definitively rule in infection. Presepsin values have a strong positive correlation with the CRP, PCT and the
SOFA and MEDS scores [13]. Higher values of presepsin are associated with septic shock compared to severe
sepsis without shock, a trend similar to that observed with PCT [1]. In probable infections with an
identifiable focus, presepsin may be of value in differentiating whether an exacerbation of chronic
obstructive pulmonary disease is due to pneumonia or non-infectious in etiology [14], and may also be useful
in patients presenting with nephrolithiasis and systemic inflammatory response syndrome (SIRS) symptoms
to rule out pyelonephritis as a cause [15], and may aid in differentiating between the causes of acute
abdomen [16]. In patients with definite pyelonephritis, a higher presepsin cutoff may be used to test for the
presence of bacteremia [17]. A similar effect was found in a study of burn patients, who are at increased risk
for severe disseminated infection [18].
In hospitalized patients or individuals already being treated in an ICU setting presepsin may retain its utility
for the diagnosis of emerging infections. In an ICU setting it may be comparable to other emerging
biomarkers, including pro-adrenomedullin [19] and soluble triggering receptor expressed on myeloid cells-1
(sTREM-1) [20], and a combination of these biomarkers may be superior for the diagnosis of sepsis compared
to either used alone. In this it could also be useful for the differential diagnosis of acute respiratory distress
syndrome (ARDS), as it appears to be elevated only in ARDS due to sepsis and not in non-infectious causes
of the syndrome [21]. Outside of the ICU, presepsin may be useful to differentiate sepsis from non-infectious
SIRS with accuracy comparable to procalcitonin [22-24]. It should be noted that although its biological
function is mostly associated with the response to gram negative bacteremia, an early study found presepsin
measurements did not differentiate gram negative and gram positive bloodstream infection [25]. Presepsin
was found to be an accurate biomarker for sepsis in geriatric individuals over 75 years of age in combination
with PCT and the early warning score [26]. It was also useful for the diagnosis of bacteremia in hematological
patients undergoing stem cell transplant with a cutoff value of 218 pg/ml [27] and in another study of
hematological patients undergoing chemotherapy was found useful for the differentiation between bacterial
and fungal infection [28]. This study confirmed the relative specificity of presepsin for bacterial infection and
the authors that elevated CRP in conjunction with presepsin within the normal reference range was in favor
of fungal infection in this group of immunocompromized individuals. A summary of the studies on the
diagnostic role of presepsin can be found in Table 1.

1 st Author and
year of
publication

Halıcı [14], 2020

Chen [20], 2020

Study design

Type of
Major findings
patients/database

Prospective
cohort study

126 patients
admitted for
COPD
exacerbation in a
single tertiary
center

Prospective
case-control

60 patients
admitted to a
single ICU with
sepsis and 60
matched controls

Presepsin at admission was accurate for diagnosing pneumonia as a cause of
acute COPD exacerbation, but a positive associated between elevated
presepsin and mortality did not reach statistical significance.

Presepsin and the biomarker sTREM-1 were more sensitive for the diagnosis
of sepsis in the ICU compared to procalcitonin and CRP, with the most
accurate indicator being a composite biomarker of presepsin and sTREM-1.
In patients diagnosed with sepsis, higher values of both biomarkers were
associated with mortality. A cutoff value of 1025 pg/ml presepsin had 83%
specificity and 85% sensitivity for the diagnosis of sepsis.

Single center
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Ruangsomboon Prospective
[26], 2020
cohort

study of 250
patients > 75
years of age
admitted on
suspicion of

Presepsin had a similar diagnostic and prognostic accuracy as procalcitonin
and the early warning score. The combination of the three biomarkers was
superior to the use of either alone, and may be useful for the timely diagnosis
of sepsis in the geriatric population.

sepsis
This prospective study enrolled 64 hematological hospitalized patients to

Stoma [28],
2019

Prospective

Hematological
patients with
sepsis

receive chemotherapy. These had proven or probable invasive fungal
infection or microbiologically proven bacterial bloodstream infection. In total,
53 patients with bacterial bloodstream infections and 11 with invasive fungal
infections participated in the study. Results showed that a combination of
CRP >120 with PCT <1.25 or presepsin <170 could be a possible combined
biomarker for invasive fungal infections in immunocompromised patients.
The values of presepsin, PCT, CRP and WBC were evaluated in patients with
sepsis and SIRS when assessed in the Emergency Department in the study

Lu [10], 2018

Prospective
cohort study

Patients with
sepsis and SIRS
in the ED

by Lu. 72 patients with sepsis and 23 patients with non-infectious SIRS were
enrolled. The levels of the above biomarkers were apparently higher in sepsis
patients than in the non-bacterial SIRS group (P < 0.05). Also, the levels of
presepsin and the APACHE II score demonstrated a significant difference
among sepsis, severe sepsis and septic shock group of patients (P < 0.05).
The authors concluded that presepsin was a promising biomarker for initially
diagnosis and risk stratification of sepsis, also a potential marker to
distinguish gram-positive and gram-negative bacterial infection.
64 ICU patients were enrolled in this case-control study, where values of

Sargentini [19],
2017

Prospective
case-control

64 ICU patients

study

inflammatory biomarkers PCT, presepsin and pro-ADM were evaluated. These
biomarkers were significantly lower in controls than in sepsis or septic shock
groups. Preliminary data showed that, despite presepsin and pro-ADM being
able to differentiate between septic and non-septic patients with accuracy,
PCT remains the most reliable marker available.
Values of presepsin were assessed in patients with acute pyelonephritis and
controls, and their capacity to predict bacteraemia on admission was

Claessens [17],

Prospective

2017

cohort study

312 patients with
acute
pyelonephritis
and bacteremia

evaluated. In 312 patients with acute pyelonephritis, presepsin concentrations
were higher than in controls, and increased in patients with bacteraemia and
in those requiring admission. Performance of presepsin to predict
bacteraemia was similar to CRP and less accurate than PCT. Although
presepsin seems to be a valuable biomarker to detect patients with acute
pyelonephritis did not offer advantage when comparing to CRP and PCT due
to mild prediction of bacteraemia and need for admission.
The diagnostic accuracy of presepsin for infection and sepsis, compared with
PCT and CRP was evaluated in the emergency department (ED) setting. 223

de Guadiana
Romualdo [11],
2017

Prospective
cohort study

223 patients with
suspected sepsis
in the ED

patients with suspected infection were enrolled in the study. Results showed
that median CRP, PCT and presepsin levels were significantly higher in
patients with infection and sepsis. PCT had the highest performance for
infection and for sepsis, PCT and presepsin performed a similar one. The
diagnostic accuracy of presepsin in this study does not improve that of PCT.

52 neutropenic
patients after

Stoma [27],
2017

Observational,
hematopoietic
prospective
stem cell
study
transplantation
(HSCT)

A prospective observational study based on data from 52 neutropenic
patients after hematopoietic stem cell transplantation (HSCT) was conducted
in order to assess the diagnostic values of presepsin, PCT, and CRP in these
patients in a condition of high prevalence of gram-negative pathogens.
Results showed the best diagnostic value for presepsin and this biomarker
may be recommended in adult patients with suspected gram-negative blood
stream infection after HSCT as a possible additional supplementary test with
a cut-off value of 218 pg/mL

Ali [22], 2016

Prospective
cohort study

51 patients with
SIRS and

Plasma presepsin, PCT and CRP levels in patients with SIRS and suspected
sepsis were serially measured in order to evaluate the diagnostic and
prognostic performance of presepsin in comparison to PCT and CRP. Results
of the study showed that presepsin and PCT yielded similar diagnostic

suspected sepsis,
accuracy, whereas presepsin performed significantly better than CRP.
25 healthy
Presepsin and PCT had comparable accuracy in differentiating between
controls
septic and non-septic patients. Finally, early changes in presepsin
concentrations might reflect the appropriateness of the therapeutic modality.
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The diagnostic accuracy of presepsin in predicting bacteraemia and bacterial
DNAaemia in patients with suspected sepsis, and its comparison with that of
PCT and CRP was assessed in this study. The presepsin median values were
Leli [23], 2016

Prospective

92 patients with

cohort study

suspected sepsis

significantly higher in bacteraemic vs non-bacteraemic patients and in
patients with bacterial DNAaemia vs patients without. This study concluded
that when sepsis is suspected, presepsin and PCT had a good diagnostic
accuracy in predicting both bacteraemia and bacterial DNAaemia, superior to
CRP.

Zhang [6], 2015

Meta-analysis

Zhang [7], 2015

Meta-analysis

Wu [8], 2015

Meta-analysis

Tong [9], 2015

Bivariate
meta-analysis

11 studies

Presepsin is an effective adjunct biomarker for sepsis diagnosis, but
insufficient to detect or rule out sepsis when used alone.

8 studies with a
total of 1,815
patients
9 studies with 10
trials and 2159
cases
11 publications
with 3,106
subjects

Presepsin exhibits a very good diagnostic accuracy for diagnosing sepsis.

Presepsin had some superiority and may be a helpful biomarker in sepsis
early diagnosis.

Valuable role in the diagnosis of sepsis, but should be interpreted carefully in
clinical practice and in comparison to traditional markers.
A prospective study aimed to evaluate the diagnostic ability of presepsin in

Hou [15], 2015

Prospective
cohort study

39 patients with
nephrolithiasis
presenting with
SIRS

the differential diagnosis between SIRS, infection, or sepsis and to compare
its diagnostic value with other used biomarkers (CRP, PCT, and WBC) in
patients of nephrolithiasis presenting with SIRS. 39 patients were enrolled in
the study and the plasma presepsin was detected by the Pathfast presepsin
assay system. ROC analysis showed that presepsin had a high diagnostic
value compared with both PCT and CRP. In the early stage of SIRS, presepsin
remained a highly sensitive and specific diagnostic marker compared with
either PCT, CRP, or WBC.

118 patients
Kweon [24],
2014

Prospective
cohort study

presenting to the
ED with

Higher diagnostic accuracy of presepsin compared to other conventional
biomarkers

suspected sepsis
226 patients with SIRS who were admitted in the Emergency Department
assessed in an attempt to compare the validity of presepsin with the
De GuardianaRomualdo [12],
2014

Prospective

226 patients with

cohort study

SIRS in the ED

commonly used available sepsis biomarkers. The results showed that
presepsin values were significantly higher in the SIRS group with bacteremia
compared to the non-bacteremic SIRS group. The best cut-off value was 729
pg/mL and this was associated with a negative predictive value of 94.4%. It
was concluded that presepsin may contribute to rule out the diagnosis of
bacteremia in SIRS patients in the ED setting.
The validity of presepsin was evaluated in the diagnosis and follow up of

Cakır Madenci

Prospective

sepsis in burn patients. A prospective study in a burn center included 37
37 sepsis patients patients. Presepsin, PCT, CRP and WBC levels were measured. Patients were

[18], 2014

cohort study

in a burn center

classified as sepsis or non-sepsis according to the American Burn
Association Consensus Criteria (ABA) 2007. The authors concluded that
presepsin plasma levels had comparable performance in burn sepsis.
A prospective study conducted in the ED enrolled 859 patients with at least 2
diagnostic criteria for SIRS. The aim was to evaluate the early diagnostic and

859 patients with
Liu [13], 2013

Prospective
cohort study

at least 2
diagnostic criteria
for SIRS in the ED

prognostic value of presepsin compared with PCT, mortality in Emergency
Department Sepsis (MEDS) score and APACHE II score in septic patients in
the ED setting. Plasma presepsin levels in septic patients were significantly
higher in non-survivors at 28 days' follow-up. Presepsin and both MEDS and
APACHE II scores were independent predictors of severe sepsis, septic shock
and 28-day mortality in septic patients. Levels of plasma presepsin were
positively correlated with PCT, MEDS score and APACHE II score in every
septic group, thus was considered a valuable marker for early diagnosis of
sepsis and risk stratification.

106 patients in
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Ulla [1], 2013

Vodnik [16],
2013

Case-control
study

Prospective
cohort study

the ED with

patients affected by SIRS but without clinical evidence of infection. The blood

suspected
sepsis/septic

samples of the patients were analyzed using the PATHFAST presepsin assay
for sCD14. In septic patients it was observed elevated presepsin

shock, and 83
patients with

concentrations on admission compared to controls. The same trend was
observed for mean values of PCT. Mean presepsin values were significantly

SIRS but without
clinical evidence

higher in non-survivor septic patients than in survivors. On the contrary, no
significant correlation was noted between PCT and survival. Presepsin had a

of infection

significant prognostic value in the population assessed in the ED.

70 patients with
bacterial and

The clinical usefulness of presepsin in the differentiation between bacterial
and non-bacterial infection in acute abdominal conditions was reported in this

non-bacterial
infection in acute

study. The presepsin values were significantly higher in patients with sepsis
than the SIRS patients. It was concluded that presepsin was a significantly

abdominal
conditions

sensitive indicator of sepsis and a useful biomarker for the rapid diagnosis of
sepsis.
207 patients were enrolled in a multi-center prospective study which aimed to

Multi-center
Endo [25], 2012

prospective
cohort study

207 patients with
bacterial and
non-bacterial
infections

assess the clinical usefulness of presepsin in bacterial and non-bacterial
infections. Levels of presepsin, PCT, and IL-6 were significantly higher in
patients with bacterial infectious disease. Presepsin levels did not differ
significantly between patients with gram+ and gram- bacterial infections. The
usefulness of presepsin for diagnosing sepsis was concluded, also presepsin
possible superiority to conventional biomarkers and blood culture.

TABLE 1: Presepsin as a diagnostic marker of infection
APACHE II: Acute physiology and chronic health evaluation II, ARDS: Acute respiratory distress syndrome, CAP: Community acquired pneumonia,
CD64: Cluster of differentiation 64, COPD: Chronic obstructive pulmonary disease, CR: Clearance ratio, CRP: C-reactive protein, DIC: Disseminated
intravascular coagulation, DNA: Deoxyribonucleic acid, ED: Emergency department, EMBASE: Excerpta medica database, hsCRP: high sensitivity
C-reactive protein, HSCT: Hematopoietic stem cell transplantation, ICU: Intensive care unit, IL: Interleukin, MEDLINE: Medical Literature Analysis
and Retrieval System Online, MEDS: Mortality in emergency department sepsis, MR-proADM: mid-regional pro-adrenomedullin, PCT: Procalcitonin,
pro-ADM: Proadrenomedullin, ROC: Receiver operating characteristic, sTREM-1: soluble triggering receptor expressed on myeloid cells-1, SCD14ST: soluble Cluster of Differentiation 14 subtype, SIRS: Systemic inflammatory response syndrome, SOFA: Sequential Organ Failure Assessment,
WBC: White blood cell.

Presepsin as a Prognostic Indicator in Sepsis
Similarly to other biomarkers of infection, serial presepsin measurements may be useful for the prognostic
stratification of septic patients. Higher measurements may be associated with greater mortality and
increased risk of the severe complications of sepsis that are typically encountered in an ICU setting,
specifically acute renal failure, septic shock, acute respiratory distress syndrome (ARDS) and disseminated
intravascular coagulation (DIC). Two meta-analyses which evaluated the prognostic role of presepsin in
septic patients have been published, one in a critical care setting [29] and the other upon admission to the
hospital [30]. By comparing the population of survivors with non-survivors both found consistently elevated
presepsin levels in non-survivors, suggesting that presepsin elevation reflects mortality risk and may be
useful as an independent predictor of mortality, thus aiding in the identification of patients most likely to
deteriorate.
Serial presepsin measurements may be used to evaluate changes in a patient’s condition in the intensive
care setting. The first few days after ICU admission are crucial, as that is when the most severe complications
of sepsis typically develop. A recent study indicated that presepsin elevation upon ICU admission and on
day 2 was a prognostic factor for acute renal failure, presepsin on days 1-3 as well as a composite factor
comprising of presepsin elevation and the Glasgow prognostic score predicted the development of ARDS,
whereas presepsin elevation on the first two days of ICU admission predicted the development of DIC [31],
findings which may be of great interests to intensivists should presepsin measurements become more widely
available. Presepsin elevation also predicts mortality in sepsis-induced ARDS [21]. In the same vein, a
marked reduction in presepsin levels may foreshadow clinical improvement, indicating response to
treatment [32]. It is clear from these results that if serial presepsin measurements are obtained a downtrend
is a good prognostic indicator while an uptrend is indicative of a worse prognosis and a more complicated
clinical course [21, 32].
Several studies in an ICU compared the prognostic utility of presepsin to other commonly used biomarkers
and clinical rating scales, including PCT, lactate, CRP, proadrenomedullin, gelactin-3 [33], and the APACHE,
MELD and SOFA scores. Presepsin consistently outperformed CRP [34,35] but was not characterized by any
significant advantage in comparison to PCT or the clinical rating scores that were examined, though its
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value may lie in the utility of its combination with other biomarkers [33,36,37]. Presepsin levels correlate
significantly with both PCT and the SOFA score and are an independent predictor of mortality in patients
treated in the ICU for sepsis [38-41], and similar findings were also observed in cohorts of hospitalized
patients not in intensive care [42,43]. Only in one cohort were there no promising results [44] at all in the
comparison between presepsin, PCT, CRP and lactate. One particularly interesting article reported on the
prognostic value of the clearance ratio of presepsin as ascertained by serial measurements which was
superior to the clearance ratio of PCT as a predictor of mortality in inpatients with severe sepsis, which
warrants further investigation [45]. One study found a sustained elevation of presepsin with simultaneous
normalization of PCT predicted relapse of sepsis, though further research is required to evaluate whether
these findings are reproducible [37].
Presepsin may also retain a significant predictive value in the emergency department setting, where initial
elevation may be a significant predictor of early mortality due to sepsis [46,47]. One study which evaluated it
along CRP, interleukin-6 and PCT reported that presepsin was the only biomarker that remained elevated
after treatment initiation in the group with the most severe initial presentation and retained an association
with an elevated risk of mortality throughout the follow-up period [48]. Another study found presepsin and
CRP elevation in the emergency room to be predictive factors of DIC, with the combination of both having a
stronger association with an increased risk of DIC than either alone [49]. These findings suggest it may be of
superior prognostic value compared to other commonly used biomarkers in the emergency setting, though
further research is required to evaluate these associations.
The prognostic utility of presepsin has also been evaluated in hospitalized patients with a known cause of
infection. Two studies on patients with confirmed pneumonia noted an association between presepsin
elevation and mortality, with presepsin elevation being more pronounced in septic patients compared to
those with the relatively milder presentation of severe pneumonia [50,51]. Similar findings were also
reported in a cohort of patients with another definite focus of infection, an enterocutaneous fistula [52]. The
authors concluded that presepsin seems to have prognostic values for source control of abdominal sepsis. A
single prospective study evaluated whether presepsin elevation could be predictive of mortality in
disseminated fungal infection with fungemia as it is in bacterial sepsis. The authors noted pronounced
presepsin elevation with normal procalcitonin, challenging the notion that presepsin is in fact specific for
bacterial infection [53]. The degree of presepsin elevation appeared to correlate with clinical severity and
mortality in patients with disseminated fungemia. A summary of studies on presepsin as a prognostic
indicator in sepsis can be found in Table 2.

1 st Author
and year of

Study design

publication

Type of
Major findings
patients/database

Shimoyama Prospective

Single center ICU,

[31], 2021

83 patients

cohort study

Presepsin elevation upon ICU admission and on day 2 was a prognostic factor for
acute renal failure, presepsin on days 1-3 as well as a composite factor
comprising of presepsin elevation and the Glasgow prognostic score predicted the
development of ARDS, whereas presepsin elevation on the first 2 days of ICU
admission predicted the development of DIC.

Aliu-Bejta

Prospective

[42], 2020

cohort study

100 patients
admitted with
sepsis in 2
tertiary care
centers

Zhao [21],
2020

Prospective
cohort study

Wen [43],

Prospective

2019

cohort study

Metaanalysis

definition. Presepsin correlated strongly with the SOFA score. CRP and
procalcitonin elevation did not differentiate between sepsis and septic shock.

Multicenter study
of 225 patients
with ARDS

Presepsin elevation enabled the discrimination of ARDS due to sepsis from ARDS
due to other causes, and quantitative presepsin levels were strongly correlated
with SOFA score and the risk of mortality in ARDS due to sepsis.

Cohort of 128
patients

Presepsin correlated strongly with the SOFA score and was an independent
predictor of in-hospital mortality. The combination of presepsin elevation with the

hospitalized due
to sepsis

SOFA score was a stronger predictor of mortality than either marker used
separately.

Critically ill adults
Kondo [29],
2019

Presepsin levels at baseline were significantly elevated in patients with septic
shock compared to patients with simple sepsis according to the sepsis-3

from MEDLINE,
EMBASE, and the
Cochrane Central
Register of
Controlled Trials
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A meta-analysis based on data from three electronic databases (MEDLINE,
EMBASE, and the Cochrane Central Register of Controlled Trials) included 19
studies with 3012 critically ill adult patients aimed to evaluate the diagnostic value
of procalcitonin and presepsin in the diagnosis of sepsis. It was showed that the
diagnostic accuracy of both biomarkers in detecting infection was similar, also
both are useful for early diagnosis of sepsis and reduction of mortality in critically
ill adults.
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The study investigated the effects of presepsin on clinical outcomes in patients
Ugajin [51],
2019

172 hospitalized
Retrospective
patients with
cohort study
pneumonia

with pneumonia based on the review of electronic medical records. The results
showed that the patients who died had higher presepsin levels on admission. The
authors concluded that in hospitalized patients with pneumonia, the plasma
presepsin levels on admission could be a useful predictor of 30-day mortality.
This retrospective study published aimed to determine the correlation between

Fujii [32],
2019

Hassan
[35], 2019

Retrospective
18 ICU patients
cohort study

Prospective
cohort study

68 ICU patients

presepsin value trend and prognosis, based on ICU sepsis patients. The results
showed that the 90-day mortality rate in the group of patients with decreased
presepsin levels significantly improved, even when presepsin values were high on
admission. The authors concluded that fifty percent decrease in presepsin levels
could be served as a useful prognostic predictor of sepsis.
An observational study was conducted on 68 ICU patients with sepsis aiming to
determine early predictors of sepsis-related in-hospital mortality, also to monitor
the levels of presepsin and hsCRP during admission in relation to the applied
treatment and the development of complications. Levels of presepsin were
significantly higher at days 0 and 3 in non-survivors vs. survivors. When compared
to hsCRP, presepsin was an early predictor of sepsis-related in-hospital mortality
in ICU patients. The authors concluded that changes in presepsin concentrations
over time may be useful for sepsis monitoring and for stratifying high-risk patients
on ICU admission that benefit from intensive treatment.
This study was intended to evaluate presepsin as a marker of diagnosing severe

Titova [50],
2018

Prospective
cohort study

75 patients with
sepsis due to
pneumonia

pneumonia and sepsis. 75 patients with pneumonia, sepsis, and other
inflammatory diseases were assessed and have been investigated for the level of
the presepsin. All enrolled patients had obtained an antibacterial therapy in other
health care centers before entering the hospital. Results showed that presepsin in
patients with pneumogenic sepsis was higher compared to presepsin of patients
with severe pneumonia and non-severe pneumonia. The high level of presepsin is
an indication of an active infectious disease and reflects the severity of the
pneumonia and development of sepsis.
This prospective study investigated the plasma levels of presepsin in fungal

Bamba

Prospective

[53], 2018

cohort study

11 patients
hospitalized for
fungal infection

bloodstream infections in relation to the disease severity and in comparison to
bacterial infections. The investigators assessed the associations of CRP,
procalcitonin, and presepsin concentrations with the severity of fungemia. Plasma
presepsin levels were found elevated in patients with fungal bloodstream infection,
with a positive relation to the disease severity. They concluded that presepsin
could be a useful biomarker of sepsis due to fungal infections.

Yang [30],
2018

Brodska
[44], 2018

Systematic
review and
meta-analysis

Prospective
cohort study

10 studies and
1617 patients

60 patients with
sepsis and SIRS

This systematic review was conducted to evaluate the mortality prediction value of
presepsin in sepsis, a total of 10 studies and 1617 patients were included. The
levels of presepsin in the first (within 24 hours) sampling were significantly lower
among survivors comparing to non-survivors. The results demonstrated some
mortality prediction value in presepsin in patients with sepsis.
Procalcitonin, C-reactive protein, presepsin and lactate were analyzed in 60
consecutive patients with sepsis and SIRS in the study. The SOFA score was
determined also daily in patients’ assessment. The results of the study showed
that presepsin did not outperform the traditional biomarkers in diagnosing sepsis
from SIRS and in mortality prognosis in critically ill patients. The authors
concluded that presepsin may have a limited adjunct value for diagnosis and early
risk stratification, performing independently of clinical illness severity.
58 ICU patients with suspected sepsis were enrolled in an observational,

Matera [38], Prospective
2017

cohort study

58 ICU patients

prospective study which aimed to evaluate the role of presepsin in predicting the
outcome in parallel with procalcitonin and CRP. Presepsin levels were significantly
higher in non-survivors vs survivors at the same time point. Presepsin
concentrations were also significantly increased in patients with positive blood
cultures. The authors concluded that presepsin has an optimal prognostic and
diagnostic value in patients with severe sepsis.

Kim [33],
2017

Retrospective Case series of
case-series
157 sepsis
study
patients
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157 septic patients were enrolled in this retrospective study. Biomarkers such as
procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2
were evaluated and their concentrations were analyzed in relation to the 30-day
all-cause mortality. Results showed a possible prognostic utility of all four
biomarkers in sepsis. This multi-biomarker approach could be a beneficial

8 of 14

approach for an optimized management of sepsis patients.

Song [52],
2016

Prospective
cohort study

61 patients with
enterocutaneous
fistula (ECF) and
abdominal sepsis

71 patients with enterocutaneous fistula were enrolled in a study when these were
diagnosed with abdominal sepsis. The aim was to evaluate the prognostic value of
presepsin in ECF. Patients with higher presepsin levels had more severe intraabdominal infection, also high risks of complications and failure of fistula closure
compared with those having lower presepsin levels. The authors concluded that
presepsin seems to have prognostic values for source control of abdominal sepsis
and clinical courses of enterocutaneous fistula.
An observational prospective study based on data from 2 ICUs in France aimed to
assess the diagnostic and prognostic value of presepsin in ICU patients with
severe sepsis, septic shock and severe community-acquired pneumonia. 144
patients were enrolled in the study. Presepsin and procalcitonin levels were

Klouche
[36], 2016

Prospective
cohort study

144 patients in 2
ICUs in France

significantly higher in septic than in non-septic patients and in patients with septic
shock. The sepsis diagnostic accuracy of presepsin was not superior to that of
PCT. In the patients admitted for respiratory failure, the capability of presepsin to
diagnose severe community acquired pneumonia (CAP) was significantly better
than PCT. Serum levels of presepsin were predictive of ICU mortality in sepsis and
in CAP patients.

EnguixArmada
[34], 2016

Carpio [47],
2015

Prospective
cohort study

Prospective
case-control
study

388 ICU patients
over 12 months
period

123 patients with
suspected
infection in the
ED and 123
healthy controls

Popa [46],

95 patients with
Retrospective suspected

2015

cohort study

infection in the
ED

A cohort study with 388 patients admitted in the ICU over a 12-month period,
assessed whether the combination of CRP, PCT, presepsin or SCD14-ST and midregional pro-adrenomedullin (MR-proADM) measured in the first 24 h from ICU
admission could offer a better diagnostic and prognostic management of septic
patients. Among the above biomarkers, PCT, MR-proADM and presepsin were
found to be complementary markers in the management of septic patients when
they were measured in the first 24 h after ICU admission.
The validity of presepsin in the Emergency Department setting was assessed in
this study of 123 patients with suspected infection and 123 healthy individuals.
Presepsin was determined on admission, after 8, 24 and 72 h. Results showed that
presepsin had a similar outcome prediction on admission to the clinical scores
MEDS and APACHE II. Combination of presepsin with MEDS score improved the
power for outcome prediction.
A retrospective study of patients with suspected infection who presented in the
Emergency Department aimed to evaluate among other parameters the
relationship between values of presepsin and clinical outcome. The authors
concluded that presepsin had a diagnostic and early prognostic value and is an
early marker of mortality in patients with sepsis.
Plasma presepsin values were measured 1, 2, and 7 days in 997 patients with

Masson
[40], 2015

Multicenter
Albumin
Italian
Outcome
Sepsis

997 patients with
severe sepsis and
septic shock

(ALBIOS) trial

severe sepsis or septic shock who were enrolled in the multicenter Albumin Italian
Outcome Sepsis (ALBIOS) trial. The association of single measurements of
presepsin or changes over time with clinical events, organ dysfunctions,
appropriateness of antibiotic therapy, and ICU or 90-day mortality were then
tested. Results of the study showed that baseline presepsin was independently
associated with the risk of ICU and 90-day mortality. Increasing concentrations of
presepsin from day 1 to day 2 were related to higher ICU and 90-day mortality.
Changes in concentrations over time seem to reflect the appropriateness of
antibiotic therapy. It was concluded that presepsin seems to be an early predictor
of host response and mortality in septic patients.

Sargentini
[37], 2015

Prospective
cohort study

Presepsin was evaluated as a potential biomarker for bacterial infection relapse in
critical care patients. 21 adult patients were studied during hospitalization in an
Italian Critical Care Unit. The results showed that in patients with a clinical
21 ICU patients

recurrence of sepsis, while procalcitonin levels were normalized during the
transient remission phase, presepsin levels remained high. The existence of
maximal presepsin levels could alert clinicians not to suspend antibiotic
treatments in sepsis patients.
A mono-centric prospective study with 116 patients with suspected severe sepsis

Behnes

Prospective

[39], 2014

cohort study

116 ICU patients
with suspected
severe sepsis or
septic shock

or septic shock aimed to evaluate the diagnostic and prognostic accuracy of
presepsin in these patients during the first week of ICU treatment. The enrolled
patients were followed up for six months and measurement of several biomarkers
was performed. Presepsin revealed a valuable diagnostic capacity to differentiate
sepsis severity compared to other used biomarkers for sepsis such as PCT, IL-6,
CRP, WBC. Presepsin and IL-6 also showed prognostic value regarding 30 days
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and 6 months all-cause mortality throughout the first week of ICU treatment.
A multicenter prospective study compared the clinical utility of presepsin with
other sepsis biomarkers including procalcitonin, interleukin-6, and CRP for
evaluating the severity of sepsis during follow-up. 103 patients with sepsis
103 patients with
Endo [48],
2014

Multicenter
prospective
cohort study

sepsis admitted
to the ED or ICU.
Also sepsis
severity scores
were calculated

admitted to the ED or ICU were enrolled and classified into 3 groups: sepsis,
severe sepsis and septic shock. The patients were further divided into the
favorable and unfavorable prognosis groups on the basis of sepsis severity scores
(i.e., SOFA and APACHE II). The patients in the favorable prognosis group had
significant decreases in all biomarker levels on days 3 and 7 after admission. In
the unfavorable prognosis group, only presepsin levels did not decrease
significantly during follow-up. This group had significantly higher 28-day mortality
than the favorable prognosis group. Presepsin levels correlated with sepsis
severity during follow-up in comparison with other conventional sepsis
biomarkers.

Ishikura
[49], 2014

Prospective
cohort study

82 patients with
≥1 SIRS criteria
who were

A study enrolled 82 patients with ≥1 SIRS criteria who were admitted in the ED,
aimed to define a biomarker panel to predict sepsis-induced disseminated
intravascular coagulation (DIC). 11 biomarkers were evaluated on ED admission.

admitted in the
ED. 11
biomarkers were
evaluated

Among the 11 biomarkers, the optimal 2-marker panel comprised presepsin and
protein C with the best accuracy of predicting sepsis. It was concluded that this
biomarker panel of presepsin and protein C is predictive of the severity of sepsisinduced DIC in suspected ED patients.
A retrospective, case-control study of a multicenter, randomized clinical trial

Masson
[41], 2014

Prospective
cohort
(ALBION
study)

Patients with
sepsis in Italian
ICUs

enrolling patients with severe sepsis or septic shock in ICUs in Italy evaluated the
prognostic value of presepsin and compared it to PCT. 50 survivors and 50 nonsurvivors at ICU discharge, matched for age, sex and time from sepsis diagnosis
were enrolled. Plasma samples were collected for 1, 2 and 7 days. Results showed
that presepsin was the only variable independently associated with ICU and 28day mortality. It also showed better prognostic accuracy than PCT in the range of
SOFA score.

TABLE 2: Presepsin as a prognostic marker in sepsis
APACHE II: Acute physiology and chronic health evaluation II, ARDS: Acute respiratory distress syndrome, CAP: Community acquired pneumonia,
CR: Clearance ratio, CRP: C-reactive protein, DIC: Disseminated intravascular coagulation, ED: Emergency department, EMBASE: Excerpta medica
database, hsCRP: high sensitivity C-reactive protein, ICU: Intensive care unit, IL: Interleukin, MEDLINE: Medical Literature Analysis and Retrieval
System Online, MEDS: Mortality in emergency department sepsis, MR-proADM: mid-regional pro-adrenomedullin, PCT: Procalcitonin, SCD14-ST:
soluble Cluster of Differentiation 14 subtype, SIRS: Systemic inflammatory response syndrome, SOFA: Sequential Organ Failure Assessment, WBC:
White blood cell.

Presepsin and Renal Failure
Due to its relatively low molecular weight, presepsin is filtered by the glomeruli in the kidneys, where it is
subsequently reabsorbed and proteolyzed in the proximal tubule. In healthy individuals, the small amounts
of presepsin produced in the absence of infection are removed from circulation primarily by the glomerular
filtration in the kidney. Thus it would be expected that patients suffering from renal failure (characterized by
a reduction of the glomerular filtration rate) would have higher baseline presepsin concentrations. This may
be particularly pronounced in dialysis-dependent individuals with end stage renal disease, as presepsin is
not filtered during dialysis. In critically ill septic patients, rapidly rising presepsin levels may be indicative of
acute renal failure, which is a grim but unfortunately common complication of sepsis.
A range of presepsin levels in the absence of acute pathology was established for individuals with normal
renal function compared with patients with chronic renal failure. Individuals with grade 3, 4 and 5 renal
failure had baseline presepsin values significantly above the other group, with values of 208.1 ± 70.2 pg/mL,
320.2 ± 170.1 pg/mL, 712.8 ± 336.3 pg/mL, respectively [54]. Three studies on patients presenting with acute
kidney injury and sepsis indicated that in the validity of presepsin measurement in this population was
reduced [55, 56] and procalcitonin was superior as a diagnostic and prognostic marker of sepsis in this group
[57]. The authors however noted that presepsin could also be used, with the caveat that a different reference
range for values be utilized and its use be limited to less severe presentations of acute renal failure (Table 3).
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1 st Author
and year of Study design
publication

Miyoshi
[54], 2019

Nakamura
[55], 2019

Crosssectional

Prospective
cohort study

Type of
patients/database
Study on the effect
kidney function on
presepsin levels in
healthy volunteers
(47) and individuals
with chronic renal
failure (85)

806 patients
with/without acute
kidney injury (AKI)

Major findings

A range of presepsin levels in the absence of acute pathology was established
for individuals with normal renal function compared with patients with chronic
renal failure. Individuals with grade 3, 4 and 5 renal failure had baseline
presepsin values significantly above the other group, with values of 208.1 ± 70.2
pg/mL, 320.2 ± 170.1 pg/mL, 712.8 ± 336.3 pg/mL, respectively.

The study assessed the validity of presepsin and procalcitonin plasma levels for
diagnosing sepsis in patients with and without acute kidney injury. Each group of
patients was subdivided according to sepsis status for each stage of the kidney
injury. The results showed that for patients with severe acute kidney injury, the
accuracy of the diagnosis of sepsis with procalcitonin was significantly higher
compared to that with presepsin.
In a retrospective study with 91 patients, the diagnostic accuracy of PCT and

Takahashi
[56], 2015

Nakamura
[57], 2014

Retrospective 91 patients
case-control
with/without acute
study

Single center
retrospective
case-control
study

kidney injury (AKI)

247 ICU patients
with/without acute
kidney injury (AKI)

presepsin was assessed when patients were divided into two groups
with/without acute kidney injury (AKI). PCT and presepsin levels were increased
significantly in the non-AKI and AKI patients with infection. It was concluded that
PCT and presepsin are useful markers of bacterial infections in AKI but different
thresholds should be applied.
A single center retrospective study referred to 247 patients admitted to the ICU
aimed to determine levels of blood presepsin in patients with or without sepsis
and among non-AKI patients or patients with different degrees of acute kidney
injury (AKI) disease. Patients were classified into non-AKI and AKI according to
the RIFLE criteria. It was finally showed that presepsin level can be a reliable
indicator of sepsis, also in sepsis patients with less severe forms of AKI.

TABLE 3: Studies on presepsin measurement interpretation in renal failure
AKI: Acute kidney injury, pg/ml: picograms per millilitre, PCT: procalcitonin, RIFLE: Risk, Injury, Failure, Loss of kidney function, and End-stage
kidney disease.

Discussion
Early diagnosis and timely treatment are the corner stones of survival improvement in sepsis syndrome.
There is still a need for identifying the ‘ideal’ biomarker as none of the common applied in clinical practice
such as the white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6
(IL-6), has a 100% sensitivity and specificity. Apart from these commonly used biomarkers, many attempts
of using molecules which are participating in the sepsis cascades failed to identify the most appropriate one
in clinical practice.
CD14, a glycoprotein expressed on monocytes and macrophages, is part of the innate immune system
serving as a receptor for lipopolysaccharides (LPS) of bacteria and activating the pro-inflammatory signaling
cascade. CD14 molecule is a pattern recognition receptor existing in two forms: a membrane-bound type
(mCD14) and a soluble form (sCD14). Both forms play a role in recognition of bacteria LPS and in cell
activation. During the progression of the sepsis cascades where the soluble CD14 fragments are cleaved, the
soluble CD14 subtype (sCD14-ST) also called as presepsin elevates significantly and is readily measured
using a chemiluminescent enzyme immunoassay. It is a small 13 kDa protein that arises due to cleavage of
the N-terminal fragment of CD14 by elastase [2]. Presepsin is filtered through the glomeruli, then
reabsorbed, and catabolized within the proximal tubular cells. Presepsin should be interpreted attentively in
patients with kidney disease, as elevated presepsin levels were found in patients with decreased renal
function, also inverse correlation has been described between presepsin and GFR as well [58,59].
This molecule is now recognized as a new sepsis biomarker and can also be used in the differentiation
between bacterial infections and non-infectious SIRS [25]. Presepsin is normally present in very low
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concentrations in the serum of healthy individuals. In response to bacterial infections, its concentration
increases within 2 hours, according to the severity of the disease and the cut-off levels for sepsis have been
reported between 400-600 pg/ml. The early increase in levels of presepsin during the sepsis cascade and
other bacterial infections have made it an attractive indicator for laboratory testing.
The findings of this review indicate that presepsin is a molecule that has been used in clinical practice the
latest years in an attempt to evaluate patients suffering from sepsis. Among the extracted bibliography,
there are some studies which do not indicate a superiority of presepsin in regards to the already used
biomarkers [12,29,37]. However, there are studies which propose presepsin as a highly sensitive and specific
marker of sepsis, as its concentration significantly correlates with the severity of sepsis syndrome and inhospital mortality [1,2,39,41]. Furthermore, some studies provide preliminary evidence that in certain
settings presepsin may be a superior diagnostic and prognostic biomarker of sepsis compared to the more
common biomarkers CRP and PCT [8,22,60,61]. Other studies also emphasize the role of presepsin in the
assessment of sepsis in combination with commonly used biomarkers and clinical rating scales, as part of a
multi-biomarker approach of sepsis in view of the absence of the ‘ideal’ biomarker [6,13,28,33]. Presepsin is
a promising biomarker for the evaluation of sepsis both in the emergency department to aid in the initial
assessment of the patient and in the intensive care setting where patients are most likely to be in a state of
multiple organ failure [34,39,40,62].
Although a strong body of literature favors the validity of presepsin as a biomarker for the diagnosis,
prognosis and risk stratification of sepsis, presepsin measurement is not yet ubiquitously available as a
routine laboratory test. The studies in favor of the use of presepsin are heterogenous, examining different
patient groups at risk of sepsis in a variety of different settings, with the small sample size being a common
limitation. Presepsin does not appear to be clearly superior to the biomarkers commonly used in the
assessment of sepsis, but may be valuable when used in conjunction with other established tests to better
identify patients at risk of clinical deterioration. Further studies are indicated to establish whether it is
useful for predicting the most severe complications of sepsis in the intensive care setting, and the evidence
regarding its use in the postoperative setting also warrants a careful appraisal.

Conclusions
Presepsin has some value in the evaluation of the severity and prognosis of sepsis and as the results of the
test are available within 2 hours, widespread clinical use is feasible, though it is unclear at this time whether
it would significantly affect clinical practice. As sepsis syndrome remains an entity with high mortality rates
and increased socioeconomic implications and the ‘ideal’ biomarker has not yet been identified, further
research is warranted to evaluate the role of presepsin alone or in combination with other biomarkers in the
assessment of sepsis.
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